203186-62-3

Upstream product

• 120-57-0 piperonal 
• 182141-70-4 N-[(1S)-1-(4-bromophenyl)ethyl]-2,2,2-trifluoroacetamide 

Downstream Products

• 376392-81-3 4-{(S)-4-[(S)-1-(4-Benzo[1,3]dioxol-5-ylmethyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 376392-77-7 (S)-1-[(S)-1-(4-Benzo[1,3]dioxol-5-ylmethyl-phenyl)-ethyl]-6-methyl-piperazine-2,5-dione 
• 376392-79-9 (S)-1-[(S)-1-(4-Benzo[1,3]dioxol-5-ylmethyl-phenyl)-ethyl]-2-methyl-piperazine 
• 376392-75-5 (S)-1-(4-Benzo[1,3]dioxol-5-ylmethyl-phenyl)-ethylamine 
• 203186-64-5 N-[1-(4-benzo[1,3]dioxol-5-ylmethyl-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 

Relevant academic research and scientific papers

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

Optimization of the piperidino-piperazines 1 and 2 provided early leads 3 and 4, which showed good activity in the CCR5-RANTES binding assay and in antiviral assays. A systematic study around these structures showed that the 2(S)-methyl piperazine is essential for CCR5 affinity, which is further enhanced by forming the 2,6-dimethyl benzamide of the piperidine.